Also in this playlist...
This transcript is automatically generated
-- theories began.
What do you study finding a drug that is effective in treating ovarian cancer researchers say that a -- and it can stabilize tumors in women.
Suffering from advanced stages of the disease extending the period.
Before the disease were sentenced.
By more than three and a half months Fox's medical eighteen -- doctor Davis's body joins us now with details.
So this is promising news ovarian cancer it is considered one of the deadliest of the G -- cancers correct.
This is a big news -- -- is this is this study that was published yesterday in New England -- medicine.
As you know ovarian cancer -- is evade did bad disease a very aggressive is that the disease.
And the purpose of this medication was really to do today possibly at survival.
What we're finding out from these two studies that there's really no survival benefit at this point but he was able to delay the progression of the disease from getting -- and by three months so it is a big news -- study from Europe wants -- from US and fox chase.
They looked at almost 2000 patients.
And did this side effects are was some issue that we've -- looked in.
And we have to be careful about this medication in the side effects and of course cost was another thing.
But I think for patients -- ovarian cancer this is a step forward it's not approved yet by FDA in this country.
Recently was the -- for breast breast cancer in November which was that created a big controversy.
And more -- obviously witnesses are hoping that this medication would come in the market.
And there are a lot of patients affected by this 25000.
New cases every year 151000.
Why wasn't an approved for breast cancer.
-- looked at the risk and benefit and I think give when -- risk outweigh the benefit they decided not to approve it.
When it comes to ovarian cancer had -- as you know it's a totally different disease than breast cancer.
This is the disease that doesn't give you much of a chance it's very hard to diagnose it.
And and when you find it a lot of -- it has spread to other organs so.
Their main standard of care right now is -- this surgery by removing the bulk of the cancer act chemotherapy.
And that's that is very interest in because he works in a different.
Mode or different track.
What it does the cancer need some -- factors.
And would qualify at the you can create these vessels -- -- that inhibits those factors so it has a different -- -- chemotherapy.
And I spoke to actually be someone my colleagues one of them is doctor Jamal ran in from mount Sinai.
Who was interest and then dug into these studies a little deeper the -- -- did you -- off this was different in Europe -- over a year so there are some flaws in his studies.
And the other thing is for selected group of patients high risk ovarian cancer is the ones that have some fluid we'll call them aside these this particular medication may war.
And I think we need further studies in the future to really give this guy a chance that at this point.
There's no major survival benefit as a result of this.
But what about the cost you mentioned that briefly.
About 50000 to 100000 dollars.
A year yes so that's the major problem side effects and the cost is a big problem you know in my own field of prostate cancer we had this policy cancer vaccine.
Called -- and Medicare approved it for a 100000 dollars a year which is a huge financial burden.
The claim was that it adds maybe two more months.
To the longevity and life of these patients I think that's a big issue.
I think as we look further into this -- perhaps we can lower the cost but that's certainly a major problem -- this medication.
My gut feeling is that if -- -- to approved money for ovarian cancer.
Because of big Ressa has the disease we'll see what happens if there's definitely.
The stepped forward as yet thank you so much static -- -- -- thanks for joining us Greg.
Filter by section